secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rapport Therapeutics, Inc. (RAPP)
CIK:        0002012593
Form:       8-K
Filed at:   2025-06-02T23:59:59+00:00
Accession:  0000950170-25-080247
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RAP-219 Phase 2a fully enrolled; topline data Sept 2025; safety profile clean
-----------------------------------------------------------------------------

- Phase 2a trial of RAP-219 in refractory focal epilepsy fully enrolled; topline results expected September 2025.
- Consolidated Phase 1 safety data (n=64) shows all TEAEs Grade 1/2, no SAEs; common: headache, dry mouth, brain fog, fatigue.
- Upcoming catalysts: initiate Phase 2a in bipolar mania Q3 2025, update on diabetic neuropathic pain program 2H 2025.
- Cash, cash equivalents and short-term investments of $285.4M as of March 31, 2025; runway through end of 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2012593/000095017025080247/0000950170-25-080247-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2012593/000095017025080247/rapp-20250602.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-080247

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer